Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Healthcare Continuum Model for Antimicrobial Washes

This article was originally published in The Tan Sheet

Executive Summary

Healthcare Continuum Model for Antimicrobial Washes: Symposium on topical antimicrobial wash products in healthcare settings, the food industry and the home, sponsored by the Cosmetic, Toiletry & Fragrance Association and the Soap & Detergent Association, will take place June 2-3 at the Washington, D.C. Marriott Hotel. Participants will include experts from FDA, CDC, USDA and academia. Industry presentations will be made by Colgate-Palmolive, Gojo Industries and P&G. The model, which assigns products into six categories depending on intended use, was discussed recently by FDA's Nonprescription Drugs Advisory Committee ("The Tan Sheet," Jan. 27, p. 5). For more information, contact Felecia Greene, CTFA, at (202) 331-1770. Registration deadline is May 20...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS086965

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel